Pal-KVK sequence activates thrombospondin-1 receptor signaling, triggering TGF-β release and downstream collagen I and IV synthesis. Complementary pathway to Matrixyl's matrikine mechanism. The combination (Matrixyl 3000) uses both peptides for dual collagen stimulation pathway activation.
Studies have administered: Topical 2–10ppm in research formulations; clinical concentration in Matrixyl 3000 formulations
In vitro: collagen I, III, and IV synthesis increase in fibroblast cultures. Clinical combination (Matrixyl 3000): 35–50% wrinkle depth reduction vs placebo in double-blind trials. Synergistic effect with palmitoyl pentapeptide-4 confirmed.
Excellent topical safety; minimal sensitization risk; no systemic concerns from topical application
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Palmitoyl Tripeptide-5 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat